modified the message; 14.2% added to or reframed the existing personalizing words (e.g., adding “because I love you”), 10.3% (45/434) added urgency to the message (e.g., “please don’t delay”) and 8% (35/434) added reassurance (e.g., “It’s really not that bad”). Almost one in five (18.3%; 80/434) deleted a negatively framed sentence on colon cancer risks. In 46.5% (195/434) of cases, the meaning of at least one sentence was changed but only 2.7% (12/434) created messages with factual inaccuracies. **Conclusions:** Modifiable messages transmitted within a social network offer a way for screened individuals to promote CRC screening. Further study is needed to identify the optimal combination of user-generated content and pre-written text, allowing for creation of messages that are acceptable to senders, persuasive, and factually accurate.

Keywords: Communication; Cancer Screening; Social Network
doi:10.3121/cmr.2013.1176.a2-3

A2-4:

Preventive Health Service Use Among Colorectal Cancer Survivors Compared to Age- and Gender-Matched Controls

Jennifer Elston Lafata¹; Ramzi Salloum¹; Paul Fishman²; Maureen O’Keeffe-Rosetti³; Debra Ritzwoller⁴; Mark Hornbrook³

¹Henry Ford Health System; ²Group Health; ³Kaiser Permanente Northwest; ⁴Kaiser Permanente Colorado

Background/Aims: Because of advances in early detection and treatment, many colorectal cancer (CRC) survivors now live for decades. Among survivors, the mortality risk from co-morbid conditions—particularly cardiovascular disease—exceeds the risk from cancer, making the receipt of routine preventive health services important in the survivor population. To date, our knowledge of preventive service use among cancer survivors, especially survivors aged <65 years, remains in its infancy. Using a case/control design, we evaluate receipt of preventive health screenings among HMO-insured CRC survivors. **Methods:** Tumor registry data available within four geographically diverse HMOs were used to identify CRC cases aged ≥50 years diagnosed with non-metastatic disease and treated with curative intent between 1/1/2000 and 12/31/2008. Age and gender distribution-matched controls without a cancer diagnosis were also identified and assigned a pseudo-diagnosis date. HMO administrative and encounter data were used to identify insurance coverage and treatment dates, and socio-demographic and health care use information. Cases and controls, stratified by age (<65 vs. ≥65), were followed annually for up to five years post-treatment. Differences in annual service use between cases and controls were evaluated using chi-square tests. **Results:** We identified N = 561 cases and N = 5,114 controls aged <65, and N = 1,268 cases and N = 13,720 controls aged ≥65. Forty six percent of both cases and controls aged <65 and 52%/53% of cases/controls aged ≥65 were female. In the first year following treatment, cases aged <65 were significantly ($P < 0.01$) more likely to use colorectal and cervical cancer screening compared to controls (59 vs. 18%, and 87 vs. 76%, respectively), but significantly less likely to undergo cholesterol testing (30 vs. 48%). An identical pattern was observed among cases aged ≥65 (47 vs. 18%, 93 vs. 79%, and 39 vs. 50%, respectively). Regardless of age, no differences were detected in use of mammography or bone densitometry among female cases and controls. These same differences and similarities persisted through the third year of follow up. **Conclusions:** CRC survivors, regardless of age, receive recommended preventive health screenings, particularly cancer screening, at rates equal to or exceeding non-cancer controls. However, CRC survivors are less likely to receive cholesterol screening, potentially increasing their risk of cardiovascular-related morbidity.

Keywords: Cancer Survivors; Preventive Health Services
doi:10.3121/cmr.2013.1176.a2-4

A2-5:

Factors Independently Associated with Receiving First-Line Bevacizumab for Advanced Non-Small Cell Lung Cancer

Thomas Delate¹; Kimberly Won¹; Nikki Carroll¹; Lawrence Kushi²; Mark Hornbrook³; Erin Bowles⁴; Debra Ritzwoller¹

¹Kaiser Permanente Colorado; ²Kaiser Permanente Northern California; ³Kaiser Permanente Northwest; ⁴Group Health

Background/Aims: Bevacizumab has FDA approval for advanced stage (IIIB/IV) non-small cell lung cancer (NSCLC) treatment; however, little is known about its uptake and use in HMOs. The aim of this study was to examine bevacizumab use over time in 4 Cancer Research Network (CRN) HMOs and identify factors associated with its use. **Methods:** Patients aged ≥21 years with stage IIIB and IV NSCLC diagnosed between 2005-2010 at 4 CRN sites who received first-line carboplatin-paclitaxel with (CPB) and without bevacizumab (CP) were included in this retrospective cohort study. Information on patients’ comorbidity burden, sociodemographic, tumor, and chemotherapy treatment characteristics over time were obtained from the site’s Virtual Data Warehouse. Patient information was contrasted between CPB and CP patient groups using chi-square tests of association and t-tests/rank sum tests for nominal/ordinal and interval-level factors, respectively. Factors with a $P < 0.2$ in the bivariate analyses and patient sex were included in a multivariate logistic regression model to identify factors independently associated with receiving first-line CPB with adjustment for the clustering of study site. Interactions of age and stage with other factors were assessed. **Results:** A total of 1109 patients were included with 198 (18%) and 911 (82%) in the CPB and CP groups, respectively. Patients who received CPB were more likely than patients who received CP to be younger with lower comorbidity burdens, well/moderate differentiated tumors, non-small cell carcinoma morphology, and diagnosed in the later years of the study (all $P < 0.05$). Receiving CPB was associated with a non-small cell carcinoma morphology (OR = 1.84, 95% CI 1.21-2.80), well/moderate differentiated tumor (OR = 1.76, 95% CI 1.14-2.74), and diagnosis year (OR = 1.17, 95% CI 1.06-1.30) while inversely associated with age at diagnosis (OR = 0.96, 95% CI 0.95-0.98) (c-statistic = 0.738). No interactions were associated. **Conclusions:** Bevacizumab use in CRN patients with NSCLC was limited but uptake was associated with younger age and tumor factors, and increased over time. The patterns of CPB use in the CRN are consistent with published data that suggest little clinical advantage of bevacizumab in NSCLC patients ≥65 years and where approximately 2/3 of NSCLC patients are diagnosed at ≥65 years.

Keywords: Lung Cancer; Chemotherapy; CRN
doi:10.3121/cmr.2013.1176.a2-5

PS1-3:

Perceptions of Cancer Screening Messages in the Media: How Do Patients Make Sense of Conflicting Messages in the Popular Media Around Cancer Screening?

Suepattra May¹; Meghan Halley¹; Katharine Rendle¹; Caroline Tietbohl¹; Dominick Frosch¹

¹Palo Alto Medical Foundation for Healthcare, Research and Education

Background/Aims: Americans are continually exposed to a message in the popular media that more healthcare services leads to better health. With respect to cancer screening, evidence-based guidelines on breast and prostate cancer screening run counter to a similar prevailing message in the popular media, which often encourages patients to “do their part” and screen for the disease. While considerable resources have been invested in the development of evidence-based decision aids (DAs) – patient education tools providing unbiased information about potential options and outcomes of a medical decision – patients may find these tools counter-intuitive because the evidence presented is often in direct contradiction to popular media depictions. Through focus groups and stimulus materials, this study investigated the influence and impact popular media has on medical decision-making for breast, colorectal and prostate cancer screening. **Methods:** Eighteen focus groups were conducted in the San Francisco Bay Area. Participants attended a group focused on screening for one of 3 cancers and completed a brief socio-demographic questionnaire. Using popular media stimulus materials and DAs, the researcher-facilitated discussions explored participants’ perceptions of and motivations to participate in cancer screening. Audiotapes of discussions were transcribed and analyzed to identify salient themes. **Results:** Ninety-two diverse participants recruited from the community participated in one of 18 focus groups (6 per condition). The average age of participants was 53, with slightly more women (55%) than men (45%). Most participants reported Caucasian ethnicity (62%) and had graduated from college (51%). Participants overwhelmingly trusted the DA over popular media stimulus materials. In deliberating the decision of whether to screen, participants drew upon their (a) personal experiences with